Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine (Seqoquel) compared with placebo in the treatment of generalized anxiety disorder

Next Previous
Trial Profile

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine (Seqoquel) compared with placebo in the treatment of generalized anxiety disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary) ; Quetiapine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms GOLD
  • Sponsors AstraZeneca

Most Recent Events

  • 06 Dec 2011 Results from a pooled analysis published in the Human Psychopharmacology: Clinical and Experimental.
  • 28 Jun 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM trials presented at the 9th World Congress of Biological Psychiatry.
  • 19 May 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM and PLATINUM trials presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top